The FDA needs to set standards for using artificial intelligence in drug development

Opinion: Poorly constructed AI algorithms for drug discovery and testing have the potential to cause harm. The FDA should play an important role in ensuring that AI-based drug development tools meet appropriate standards.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.
White Papers

Using AI-based Prognostic Models to Design Efficient, Unbiased Clinical Trials

Webinars

Part 3: Innovation in Clinical Research: AI-based Drug Development Tools and the Regulatory Landscape‍

Webinars

Part 2: Faster, More Efficient Trials: Novel Trial Designs using Digital Twins‍

Watch an overview of specific use cases for Digital Twins and learn how novel trial designs with Digital Twins enable smaller trials that maintain their power.
Watch a panel discussion on the regulatory landscape where experts share perspectives on the future of AI-based drug development tools like Digital Twins.
Statistical principles of clinical trials with Digital Twins